Collectively, these results show that pharmacological inhibition of USP25 leads to reduced HIF-1α activity specifically in PDAC tumor cells, which impairs their survival in the hypoxic tumor microenvironment, and subsequently leads to a reduction in PDAC tumor growth in vivo (Supplementary Fig. 12). This evidence concerns the gene USP25 and neoplasm.